Evidence map›Paper›PMID 33225206›Full record

ArticleJNCI cancer spectrum2020

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.

Aser Abrha, Navika D Shukla, Rachel Hodan, Teri Longacre, Shyam Raghavan, Colin C Pritchard, George Fisher, James Ford, Sigurdis Haraldsdottir

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  6. Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aser AbrhaDivision of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, CA, USA.
Navika D ShuklaSchool of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1129-545X
Rachel HodanCancer Genetics and Genomics, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5439-295X
Teri LongacreDepartment of Pathology, Stanford University, Stanford, CA, USA.
Shyam RaghavanDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3816-1542
Colin C PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA.
George FisherDivision of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, CA, USA.
James FordDivision of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, CA, USA.
Sigurdis HaraldsdottirDivision of Medical Oncology, Department of Internal Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-5050-3699
Stanford University · USCancer Genetics (United States) · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn light of recent Food and Drug Administration (FDA) approval of immune checkpoint inhibitors for mismatch repair deficient (dMMR) malignancies, identifying patients with dMMR malignancies has become increasingly important. Although screening for dMMR in colorectal cancer (CRC) is recommended, it is less common for extracolonic gastrointestinal (GI) malignancies. At Stanford Comprehensive Cancer Institute (SCCI), all GI malignancies have been screened for dMMR via immunohistochemistry since January 2016.

methodsIn this study, we conducted a retrospective review of all patients with GI malignancies screened for dMMR between January 2016 and December 2017. Tumor sequencing was performed on cases negative for germline pathogenic variants where tumor material was available.

resultsA total of 1425 consecutive GI malignancies were screened for dMMR at SCCI during the study period, and 1374 were included for analysis. dMMR was detected in 7.2% of all GI malignancies. We detected the highest prevalence of dMMR in gastric (15 of 150, 10.0%) followed by colorectal (63 of 694, 9.1%), pancreatic (13 of 244, 5.3%), and gastroesophageal malignancy (6 of 132, 4.5%) patients. Lynch syndrome was the most common etiology for dMMR in colorectal cancer (41.5%), double somatic (confirmed or possible) pathogenic variants the most common etiology in pancreatic cancer (44.4%), and somatic

conclusionsGiven the relatively high incidence of dMMR in GI malignancies, we recommend screening all GI malignancies. Our results suggest that although a rare occurrence, double somatic pathogenic variants may be a biologically significant pathway causing dMMR in pancreatic cancer.

Identifiers

PMID33225206
PMCPMC7667994
OpenAlexW3036677430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.